SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
2.270
+0.010 (0.44%)
At close: Sep 5, 2025, 4:00 PM
2.230
-0.040 (-1.76%)
After-hours: Sep 5, 2025, 6:07 PM EDT

SAB Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2020
24356330340-
Upgrade
Market Cap Growth
-43.00%-44.79%113.36%-91.25%--
Upgrade
Enterprise Value
2496627336-
Upgrade
Last Close Price
2.263.796.885.9078.10-
Upgrade
PS Ratio
182.9426.4828.331.245.58-
Upgrade
PB Ratio
1.751.351.110.968.81-
Upgrade
P/TBV Ratio
1.951.351.110.968.81-
Upgrade
P/OCF Ratio
----170.89-
Upgrade
EV/Sales Ratio
209.926.9129.321.145.51-
Upgrade
Debt / Equity Ratio
0.530.180.100.190.220.21
Upgrade
Debt / EBITDA Ratio
-----0.38
Upgrade
Asset Turnover
0.000.020.030.360.881.48
Upgrade
Quick Ratio
0.542.615.231.371.563.00
Upgrade
Current Ratio
0.872.985.451.471.903.12
Upgrade
Return on Equity (ROE)
-127.48%-81.92%-95.51%-53.85%-44.21%86.15%
Upgrade
Return on Assets (ROA)
-56.81%-41.86%-35.30%-27.37%-12.16%34.47%
Upgrade
Return on Capital (ROIC)
-74.79%-57.16%-47.50%-43.00%-17.77%41.14%
Upgrade
Return on Capital Employed (ROCE)
-----45.20%
Upgrade
Earnings Yield
-158.54%-97.39%-66.52%-63.04%-5.05%-
Upgrade
FCF Yield
-132.33%-98.89%-39.91%-86.20%-2.64%-
Upgrade
Buyback Yield / Dilution
-21.75%-67.74%-26.86%-59.20%-1.21%23.30%
Upgrade
Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q